rheumatoid arthritis
Conditions
Interventions
Adalimumab full dose group (Adalimumab, 40mg/2 weeks, subcutaneous injection):None
Adalimumab tapering group (Adalimumab tapering combined with methotrexate therapy. The recommended dosage of adalimumab is as follows: Adalimumab, 40mg/2 weeks, subcutaneous injection, reduce the dose
"Triple therapy" group (triple therapy is applied. According to the patient's condition and willingness of patients, three traditional synthetic anti-rheumatic drug combination treatment could be appl
Leflunomide, 10-20mg once daily
Sulfasalazine, orally, 500mg-1000mg each time, 3-4 times a day
Hydroxychloroquine, orally, 0.2g to 0.4g, once a day.):None
Sponsors
School of clinical medicine & the first affiliated hospital of chengdu Medical college
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) voluntary informed consent; (2) Meet the RA classification standard of ACR 1987 or the RA classification standard of ACR/EULAR 2010; (3) Current initiation or preparation of adalimumab or "triple therapy" as assessed by the clinician.
Exclusion criteria
Exclusion criteria: (1) in the systemic acute or chronic infection period, or have a history of active tuberculosis; (2) malignant tumor subjects; (3) Moderate to severe heart failure (New York Heart Society grades 3-4); (4) Pregnant and lactating women; (5) Allergic to the ingredients of the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DAS28 score;Total cost;HAQ score; | — |
Countries
China
Contacts
Public ContactDang Wantai
School of clinical medicine & the first affiliated hospital of chengdu Medical college
Outcome results
None listed